Document Detail

IL-23 promotes growth and proliferation in human squamous cell carcinoma of the oral cavity.
MedLine Citation:
PMID:  20428758     Owner:  NLM     Status:  MEDLINE    
Interleukin (IL)-23 is a heterodimeric cytokine, comprising IL-12p40 and the cloned IL-23-specific p19 subunit, was identified as a cancer-associated cytokine in a recent study. Like IL-12, IL-23 is expressed predominantly by activated dendritic cells and phagocytic cells. These cytokines antagonistically regulate local inflammatory responses in the tumor microenvironment and infiltration by intraepithelial lymphocytes. We have previously demonstrated the expression of IL-23 and its receptors in human oral squamous cell carcinoma (HOSCC) cell lines and tissue. Hence, this study investigated whether IL-23 has a role in the growth and proliferation of oral cancer cells by examining the expression kinetics of IL-23 and NF-kappaB activity, in vitro and in vivo. IL-23, which constitutively expressed in oral cancer, was enhanced by TNF-alpha and IL-23. IL-23 promotes cell proliferation in oral cancer and enhances the transport of nuclear factor-kappaB (NF-kappaB p65, RelA) to the nucleus in HSC-3 cells. Furthermore, luciferase reporter assay showed that IL-23 strongly induces RelA activity, and confirmed this finding by knockdown of IL-23 using RNA interference. Although RelA activity was down-regulated by anti-human IL-23p19 polyclonal antibody, used to neutralize the activity of IL-23, apoptosis was not induced. Immunohistochemistry revealed a weak IL-23 immunoreactivity in the cytoplasm of inflammatory infiltrating cells and in the cancer cells derived from 14 of 40 cases (35%) of oral SCC. In contrast, strong RelA immunoreactivity was observed in 30 of 40 cases of SCC (75%), especially consistent with IL-23 positive cells in SCC tissues. These data suggest that IL-23 up-regulates the growth and cell proliferation of oral cancer by promoting the nuclear transactivation of RelA.
Masakatsu Fukuda; Masahiro Ehara; Seiji Suzuki; Yoshihiro Ohmori; Hideaki Sakashita
Related Documents :
11205308 - The effects of gossypol on the invasiveness of mat-lylu cells and mat-lylu cells from t...
1442018 - Immunohistochemical detection of epidermal growth factor receptor in laryngeal squamous...
7338968 - Desmosomes and gap junctions in precarcinomatous and carcinomatous conditions of squamo...
8862728 - Antitumor activity of 2-amino-4,4 alpha-dihydro-4 alpha, 7-dimethyl-3h-phenoxazine-3-on...
2844898 - Cytotoxic lymphocyte-derived lytic granules do not induce dna fragmentation in target c...
8445028 - The role of progesterone in regulating human granulosa cell proliferation and different...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of oncology     Volume:  36     ISSN:  1791-2423     ISO Abbreviation:  Int. J. Oncol.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-04-29     Completed Date:  2010-08-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9306042     Medline TA:  Int J Oncol     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  1355-65     Citation Subset:  IM    
Second Division of Oral and Maxillofacial Surgery, Department of Diagnostic and Therapeutic Sciences, Meikai University School of Dentistry, Sakado, Saitama 350-0283, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Carcinoma, Squamous Cell / genetics,  metabolism*,  pathology
Cell Line, Tumor
Cell Proliferation
Enzyme-Linked Immunosorbent Assay
Gene Expression Regulation, Neoplastic / genetics*
Interleukin-23 / metabolism*
Middle Aged
Mouth Neoplasms / genetics,  metabolism*,  pathology
NF-kappa B / genetics,  metabolism
RNA, Small Interfering
Reverse Transcriptase Polymerase Chain Reaction
Transcription Factor RelA / genetics,  metabolism*
Transcriptional Activation
Tumor Necrosis Factor-alpha / metabolism
Reg. No./Substance:
0/Interleukin-23; 0/NF-kappa B; 0/RELA protein, human; 0/RNA, Small Interfering; 0/Transcription Factor RelA; 0/Tumor Necrosis Factor-alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Noteworthy clinical case studies in cancer gene therapy: tumor-targeted Rexin-G advances as an effic...
Next Document:  Gene expression profiling predicts response to temozolomide in malignant gliomas.